Stockscreener 앱 받기
164.08
0.02%
0.03
시장 영업 전:
164.08
전일 마감가:
$164.05
열려 있는:
$164.02
하루 거래량:
425.70K
Relative Volume:
0.66
시가총액:
$8.39B
수익:
$638.50M
순이익/손실:
$-183.17M
주가수익비율:
-44.41
EPS:
-3.6943
순현금흐름:
$-93.89M
1주 성능:
-0.09%
1개월 성능:
-11.57%
6개월 성능:
+31.89%
1년 성능:
+30.67%
1일 변동 폭
$163.22
$166.09
1주일 범위
$160.10
$168.00
52주 변동 폭
$86.99
$191.50
Axsome Therapeutics Inc Stock (AXSM) Company Profile
명칭
Axsome Therapeutics Inc
전화
(212) 332-3241
주소
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
164.08 | 8.39B | 638.50M | -183.17M | -93.89M | -3.6943 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-01 | 개시 | B. Riley Securities | Buy |
| 2025-09-03 | 재개 | Wells Fargo | Overweight |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-06-03 | 개시 | Oppenheimer | Outperform |
| 2025-04-07 | 개시 | Jefferies | Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-12-31 | 재확인 | Mizuho | Outperform |
| 2024-09-03 | 개시 | Wells Fargo | Overweight |
| 2024-08-06 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-07-22 | 개시 | Needham | Buy |
| 2024-04-29 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | 개시 | Robert W. Baird | Outperform |
| 2024-02-06 | 개시 | UBS | Buy |
| 2024-01-25 | 개시 | RBC Capital Mkts | Outperform |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-08-08 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-01-05 | 개시 | Piper Sandler | Neutral |
| 2022-11-01 | 개시 | Loop Capital | Buy |
| 2022-09-07 | 재개 | Mizuho | Buy |
| 2021-08-10 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | 개시 | Berenberg | Buy |
| 2021-01-08 | 개시 | Jefferies | Buy |
| 2020-12-16 | 개시 | Mizuho | Buy |
| 2020-09-29 | 개시 | BofA Securities | Underperform |
| 2020-09-10 | 개시 | Morgan Stanley | Overweight |
| 2020-04-28 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-14 | 개시 | Cowen | Outperform |
| 2019-12-30 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-17 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-16 | 재확인 | Guggenheim | Buy |
| 2019-10-16 | 개시 | Guggenheim | Buy |
| 2019-09-18 | 개시 | William Blair | Outperform |
| 2019-05-28 | 개시 | SunTrust | Buy |
| 2019-05-23 | 재확인 | H.C. Wainwright | Buy |
| 2019-04-08 | 개시 | SVB Leerink | Outperform |
| 2019-03-15 | 재확인 | H.C. Wainwright | Buy |
| 2016-10-03 | 재개 | Brean Capital | Buy |
| 2015-12-15 | 개시 | Cantor Fitzgerald | Buy |
| 2015-12-14 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Axsome Therapeutics Inc 주식(AXSM)의 최신 뉴스
Royce & Associates LP Raises Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics, Inc. $AXSM Shares Sold by Intech Investment Management LLC - MarketBeat
Axsome Therapeutics, Inc. $AXSM Position Boosted by TD Asset Management Inc - MarketBeat
AXSM: Robust late-stage pipeline and sales force expansion drive growth across CNS and pain markets - TradingView
AXSM: AUVELITY and pipeline assets drive growth, with key FDA decisions and launches ahead - TradingView
Axsome Therapeutics (AXSM): Analyst Consensus Highlights 35% Potential Upside for This Biotech Innovator - DirectorsTalk Interviews
Axsome Therapeutics Aktie: Wachstumskurs bestätigt - sharewise.com
DNB Asset Management AS Increases Stock Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics, Inc. $AXSM Shares Bought by JPMorgan Chase & Co. - MarketBeat
Axsome Therapeutics, Inc. (AXSM): A Bull Case Theory - Bitget
Axsome Explores Solriamfetol In Phase 3 CLARITY Trial For MDD Subset - Sahm
Citigroup Inc. Boosts Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) COO Sells $5,726,990.64 in Stock - MarketBeat
Mark Coleman Sells 25,000 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Axsome (NASDAQ: AXSM) CEO awarded 54,623 RSUs vesting by 2030 - Stock Titan
[Form 4] Axsome Therapeutics, Inc. Insider Trading Activity - Stock Titan
Axsome Therapeutics (AXSM) director completes 25,000-share 10b5-1 sale - Stock Titan
Axsome Therapeutics Executives Sell Shares Worth Over $9.7 Million - TradingView
Axsome Opens CLARITY Trial As Solriamfetol Targets Underserved MDD Patients - Yahoo Finance
Axsome’s $7.75 Million Investor Settlement Gets Court Sendoff - Bloomberg Law News
Q1 EPS Estimate for Axsome Therapeutics Reduced by Analyst - MarketBeat
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS), Ionis Pharmaceuticals (IONS) and Axsome Therapeutics (AXSM) - The Globe and Mail
Axsome Therapeutics’ Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For Stock - Stocktwits
AXSM (NASDAQ: AXSM) affiliate to sell 35,378 Class A shares via cashless exercise - Stock Titan
Smart Money Is Betting Big In AXSM OptionsAxsome Therapeutics (NASDAQ:AXSM) - Benzinga
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders - Benzinga
Axsome Therapeutics, Inc. $AXSM Shares Purchased by Vanguard Group Inc. - MarketBeat
Axsome Therapeutics Highlights Auvelity Momentum, 600-Rep Sales Push, and April 30 ADA PDUFA at Oppenheimer Conf. - MarketBeat
Axsome Therapeutics (AXSM) director exercises 6,250 options and holds shares - Stock Titan
Axsome Therapeutics at Oppenheimer Conference: Strategic Focus on Growth By Investing.com - Investing.com Australia
Axsome Therapeutics at Oppenheimer Conference: Strategic Focus on Growth - Investing.com
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q4 2025 Earnings Call Transcript - Insider Monkey
Axsome Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Wolfe Research initiates Axsome stock with outperform rating By Investing.com - Investing.com Canada
Axsome Therapeutics (NASDAQ:AXSM) Raised to Strong-Buy at Wolfe Research - MarketBeat
Axsome (AXSM) Q4 2025 Earnings Call Transcript - AOL.com
Dana Investment Advisors Inc. Grows Stock Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Patent Deal Extends Sunosi Horizon And Clarifies Revenue Outlook - Sahm
Guggenheim Raises Axsome Therapeutics (AXSM) Price Target to $22 - GuruFocus
UBS raises Axsome Therapeutics stock price target on sales force expansion - Investing.com Nigeria
Axsome Therapeutics’ Q4 numbers beat Wall Street expectations: Analyst sees over 23% upside for stock - MSN
AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales - Finviz
Axsome Therapeutics (AXSM) Receives Updated Analyst Rating and T - GuruFocus
UBS Adjusts Axsome Therapeutics Price Target to $251 From $248, Maintains Buy Rating - marketscreener.com
Wolfe Research initiates Axsome stock with outperform rating - Investing.com
Axsome Therapeutics Q4 Revenue Surge Tests Bulls’ Profitability Narrative - simplywall.st
This Gentherm Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Wolfe Research Initiates Coverage of Axsome Therapeutics (AXSM) with Outperform Recommendation - Nasdaq
RBC Raises Price Target on Axsome Therapeutics to $222 From $219, Keeps Outperform Rating - marketscreener.com
Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms - The Manila Times
Axsome Therapeutics initiates clarity phase 3 trial of solriamfetol in adults with major depressive disorder - marketscreener.com
Axsome Therapeutics Inc (AXSM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Axsome Therapeutics Inc 주식 (AXSM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Jacobson Mark L. | Chief Operating Officer |
Feb 26 '26 |
Option Exercise |
2.85 |
35,378 |
100,827 |
35,378 |
| Jacobson Mark L. | Chief Operating Officer |
Feb 26 '26 |
Sale |
161.88 |
35,378 |
5,726,991 |
0 |
0.11%
6.00%
자본화:
|
볼륨(24시간):